Cost-utility analysis of primary prophylaxis versus treatment on-demand for individuals with severe haemophilia.
OBJECTIVE
To assess the cost effectiveness of primary prophylaxis with clotting factor instead of treatment following a bleed (on-demand) for individuals with severe haemophilia.


METHODS
Different data sources on the clinical effects and costs of treatments were combined using a Markov model.


METHODS
English treatment centres.


CONCLUSIONS
UK societal.


METHODS
Hypothetical cohorts of 100 individuals with severe haemophilia A or B or severe von Willebrands disease.


METHODS
Primary prophylaxis treatment on-demand with clotting factor.


METHODS
Costs, quality-adjusted life-years (QALYs) and incremental cost per QALY in UK pounds ( pound, 1999/2000 values).


RESULTS
The baseline results showed that treating individuals with severe haemophilia A/severe von Willebrands disease or severe haemophilia B with primary prophylaxis instead of treatment on-demand cost an additional pound 46500 and pound 8600 per QALY gained, respectively. However, the results were extremely sensitive to a number of factors including the clotting factor unit cost, the time between prophylactic doses and the discount rate.


CONCLUSIONS
Despite the high costs of treatment, primary prophylaxis was cost effective compared with treatment on-demand in some scenarios. Primary prophylaxis is more likely to be cost effective for individuals with severe haemophilia B compared with individuals with severe haemophilia A/severe von Willebrands disease. Further research is required to assess the relationship between methods of clotting factor infusion and health-related quality-of-life.
Miners
Alexander H
AH
Health Economics Research Group, Brunel University, Uxbridge, United Kingdom. aminers@nice.nhs.uk
Sabin
Caroline A
CA
Tolley
Keith H
KH
Lee
Christine A
CA
D001779:Blood Coagulation Factors / Q000191:economics / Q000627:therapeutic use; D015331:Cohort Studies; D003362:Cost-Benefit Analysis; D006467:Hemophilia A / Q000191:economics* / Q000517:prevention & control / Q000628:therapy*; D006760:Hospitalization; D006801:Humans; D008390:Markov Chains; D018803:Models, Economic; D006113:United Kingdom
D001779:Blood Coagulation Factors